Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Applications of composition of ligustrazine and mannuronic acid in preparation of medicines for treating thrombotic diseases and nervous system diseases

A technology of mannuronic acid and thrombotic diseases, applied in the field of medicine, to achieve good market application prospects, prevent and treat thrombotic diseases, and strong thrombotic diseases

Active Publication Date: 2020-02-07
OCEAN UNIV OF CHINA
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Xu Juan et al. disclosed the drug co-crystal of ethinylestradiol and ligustrazine and its application in CN201910378502; Zheng Jianyong et al. disclosed the ligustrazine phosphate compound and the pharmaceutical composition containing the ligustrazine compound and ginkgo leaf active ingredients in 201410092322; Cai Jun in In CN 200610153342, the medicinal composition of Ligustrazine and Rhodiola Rosea is disclosed; however, there is no report that Ligustrazine and mannuronic acid are used in combination for related diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of composition of ligustrazine and mannuronic acid in preparation of medicines for treating thrombotic diseases and nervous system diseases
  • Applications of composition of ligustrazine and mannuronic acid in preparation of medicines for treating thrombotic diseases and nervous system diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Embodiment 1: The effect of oral administration of ligustrazine and mannuronic acid on platelet aggregation in experimental rats

[0023] Select SD rats, male, 3-4 weeks old, provided by the Experimental Animal Center of Shandong Province. Experimental animals were divided into 5 groups, 6 in each group, control group, Ligustrazine 100mg / kg; Mannucuronic acid 200mg / kg; kg; intragastric administration; once a day, continuous administration for one week, after the experiment, fix the rats on the operating table, puncture the heart with a needle to take blood, and anticoagulate with sodium citrate at the same time, centrifuge at 1000rpm for 10 minutes, and absorb the supernatant The liquid is platelet-rich plasma PRP; the remaining blood is centrifuged again at 3000rpm for 20 minutes, and the supernatant is platelet-poor plasma PPP. Adjust PRP with PPP Platelet count is 4X10 8 / ml. Adjust to zero with PPP, add PRP to the pen cloud tube, warm bath at 37°C for 10 minutes,...

Embodiment 2

[0028] Embodiment 2: The effect of oral ligustrazine and mannuronic acid on rabbit platelet aggregation

[0029] New Zealand rabbits were selected as experimental animals, weighing 2-3 kg, male, and provided by the Experimental Animal Center of Shandong Province. Experimental animals were divided into 5 groups, 6 in each group, control group, Ligustrazine 100mg / kg; Mannucuronic acid 200mg / kg; kg; intragastric administration; once a day, continuous administration for one week, after the experiment, fix the rabbit supine on the operating table, puncture the heart with a needle to take blood, anticoagulate with sodium citrate, centrifuge at 1000rpm for 10 minutes, and draw up The supernatant is platelet-rich plasma PRP; the remaining blood is centrifuged again at 3000rpm for 20 minutes, and the supernatant is platelet-poor plasma PPP. PRP platelet count was adjusted to 4X108 / ml with PPP. Adjust to zero with PPP, add PRP to the pen cloud tube, warm bath at 37°C for 10 minutes, a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides applications of a composition of ligustrazine and mannuronic acid in preparation of medicines for treating thrombotic diseases and nervous system diseases. Test resultsshow that compared with single drug administration of ligustrazine and mannuronic acid, a combined drug administration of the ligustrazine and mannuronic acid produces a synergistic anti-platelet aggregation effect which is significantly better than that of single drug administration. The combined combination of the ligustrazine and mannuronic acid can play functions from different approaches andthus synergistically plays a stronger role in preventing and treating the thrombotic diseases. The combined combination of the ligustrazine and mannuronic acid can be used for treating central nervoussystem disorders and circulatory disorders caused by the thrombotic diseases and thrombus, and has a good market application prospect.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of a composition of ligustrazine and mannuronic acid in the preparation of medicines for treating thrombotic diseases and nervous and circulatory system diseases. Background technique [0002] Cardiovascular and cerebrovascular diseases are a class of diseases that seriously threaten human life and health in today's society. Clinically, they are manifested as cardiovascular and cerebrovascular ischemia or hemorrhage. According to WHO estimates, by 2020, 4 million people in my country will die of cardiovascular and cerebrovascular diseases every year. Stroke is also known as stroke or cerebrovascular accident. The main clinical manifestations are cerebral ischemia and hemorrhagic injury. Fifteen million people worldwide suffer from stroke every year. In my country, stroke is the leading cause of human death. The number one cause of disability and the t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7012A61K31/4965A61P7/02A61P9/14A61P25/00A61P13/12A61P25/28A61P9/00
CPCA61K31/4965A61K31/7012A61P7/02A61P9/14A61P25/00A61P13/12A61P25/28A61P9/00A61K2300/00
Inventor 郝杰杰王鹏李海花
Owner OCEAN UNIV OF CHINA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com